Navigation Links
Excellent Results Received from GeoVax's Full-Dose HIV/AIDS Vaccine Trial
Date:11/2/2007

responses

Two additional Phase 1 human trials testing different vaccine regimens started in June 2007 and are currently in process. Planning of a large Phase 2 trial is underway and tentatively scheduled for a mid-2008 start.

"These results extend the earlier positive results for both our full and 1/10th dose groups to a larger number of volunteers," says Dr. Harriet Robinson, GeoVax Chief Scientific Advisor. "They are extremely encouraging and provide a strong foundation for proceeding with phase 2 human testing."

The human trials, testing GeoVax's HIV/AIDS vaccines, are conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded and supported by the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of HIV/AIDS vaccines. Preclinical work enabling the development of the clinical evaluation of GeoVax's DNA and MVA vaccines was funded by the National Institute of Allergy and Infectious Diseases of the US National Institute of Health. The NIH recently provided additional support to GeoVax's vaccine development program in the form of a $15 million IPCAVD grant awarded in October 2007.

About GeoVax Labs, Inc. (http://www.geovax.com)

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is protected by 20 filed patent applications and issued patents.

GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, by vaccinating individuals prior to infection with the AIDS virus. In addition, GeoVax AIDS vaccines may be effective as therapeutics (treatment of people infected with AIDS virus). Studies evaluating the
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
2. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
3. Avant’s Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential
4. Avants Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential
5. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
6. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
7. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
8. Sygnis Pharma AG announces date for presentation of clinical results
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
11. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Champions Biotechnology, Inc . (OTC Bulletin Board: CSBR), ... preclinical platforms and tumor specific data to enhance ... financial results for the second fiscal quarter ended ... financial results are available in the Company,s Form ... for the second quarter of 2010 were $1,289,000 ...
(Date:12/15/2009)... 15 The U.S. Food and Drug Administration ... voted 12 yes, 4 no, and 1 abstention that ... risks to support the use of CRESTOR® (rosuvastatin calcium) ... greater than or equal to 50 years, women greater ... LDL < 130 mg/dL; hsCRP greater than or equal ...
(Date:12/15/2009)... -- Dakim, Inc. and Alzheimer,s Weekly today announced the ... Health Contest, designed to help five seniors in their ... disease. All five winners will receive a $2,500 Dakim ... seniors preserve their brain health and the most widely ... across the country. ,, The contest, held ...
Breaking Medicine Technology:Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results 5Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 3Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 4Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 55 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 25 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 3ImaginAb Inc and BZL Biologics LLC Conclude Licensing Agreement for Imaging Rights to huJ591 Prostate Specific Membrane Antigen 28PSMA 29 14433 1ImaginAb Inc and BZL Biologics LLC Conclude Licensing Agreement for Imaging Rights to huJ591 Prostate Specific Membrane Antigen 28PSMA 29 14433 2Aprimas EHR Helps Bend Urology Associates Improve Efficiency Workflow 5391 1Aprimas EHR Helps Bend Urology Associates Improve Efficiency Workflow 5391 2Aprimas EHR Helps Bend Urology Associates Improve Efficiency Workflow 5391 3Ethicon Endo Surgery Launches New Echelon Flex 28TM 29 Endopath 28R 29 Stapler That Delivers Echelon 28TM 29 Compression Now With Natural Articulatio 5387 1Ethicon Endo Surgery Launches New Echelon Flex 28TM 29 Endopath 28R 29 Stapler That Delivers Echelon 28TM 29 Compression Now With Natural Articulatio 5387 2Ethicon Endo Surgery Launches New Echelon Flex 28TM 29 Endopath 28R 29 Stapler That Delivers Echelon 28TM 29 Compression Now With Natural Articulatio 5387 3Ethicon Endo Surgery Launches New Echelon Flex 28TM 29 Endopath 28R 29 Stapler That Delivers Echelon 28TM 29 Compression Now With Natural Articulatio 5387 4Ethicon Endo Surgery Launches New Echelon Flex 28TM 29 Endopath 28R 29 Stapler That Delivers Echelon 28TM 29 Compression Now With Natural Articulatio 5387 5Ethicon Endo Surgery Launches New Echelon Flex 28TM 29 Endopath 28R 29 Stapler That Delivers Echelon 28TM 29 Compression Now With Natural Articulatio 5387 6Ethicon Endo Surgery Launches New Echelon Flex 28TM 29 Endopath 28R 29 Stapler That Delivers Echelon 28TM 29 Compression Now With Natural Articulatio 5387 7Ethicon Endo Surgery Launches New Echelon Flex 28TM 29 Endopath 28R 29 Stapler That Delivers Echelon 28TM 29 Compression Now With Natural Articulatio 5387 8Ethicon Endo Surgery Launches New Echelon Flex 28TM 29 Endopath 28R 29 Stapler That Delivers Echelon 28TM 29 Compression Now With Natural Articulatio 5387 9
... 10 Diplomat Specialty,Pharmacy announced today that Teva ... of only three sites to participate in a ... (TOP MS)., The goal, of the two ... benefits of a,specialty pharmacy therapy management program on ...
... Medical,Innovations, Inc. (Amex: IMA ), a ... management solutions, met yesterday with,Ban Ki-moon, the ... of a,group of senior executives of seventeen ... and diagnostic companies.,Inverness, together with senior officials ...
Other Medicine Technology:Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS) 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 3
(Date:12/15/2009)... of the U.S. Senate to allow importation of ... more effective direct bulk purchasing of prescription drugs, ... industry controls the health reform debate, according Consumer ... Dorgan (D-ND) was a relatively modest proposal, far ... to directly negotiate discounts with drug manufacturers," said ...
(Date:12/15/2009)... SUNNYVALE, Calif., Dec. 15 Palo Alto ... Shinshu University has deployed its PA-4000 Series next-generation ... network and for enhanced visibility and control over ... University is a Japanese national university with eight ... in 1949 by integrating a number of academic ...
(Date:12/15/2009)... where all couples of reproductive age were evaluated, Italian ... The number of children born with cystic fibrosis decreases ... mutation carriers increases, a new study finds. , CF ... northeast Italy for many years. Since the 1990s, the ... number of infants born with CF. , Two different ...
(Date:12/15/2009)... cancer tests promised but not delivered ,, ... calls on Congress to ensure that healthcare reform ... currently required of insurance companies in 37 states. ... those segments of the population and individuals who ... men and men who have a family history ...
(Date:12/15/2009)... Patient advocate Betsy McCaughey, Ph.D., will ... "it doesn,t matter whether there,s a public option. The ... option - give government authority over how your doctor ... social agenda by shifting billions of dollars from Medicare ... and local politicians." ,, Betsy McCaughey is ...
Breaking Medicine News(10 mins):Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 2Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 3Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Wider Adult Screening May Mean Fewer Children With Cystic Fibrosis 2Health News:Men's Health Network Calls on Congress to Complete President Obama's Promise on Health Care Reform 2
... Cancer Society (SCS) Singapore have started a month-long prostate screening ... to reach out to more Singaporean men between the ages ... the warning signs of prostate disease and encourage early treatment. ... Awareness Month said: “Prostate disease affects up to half of ...
... the setbacks the Novartis seems to be receiving in its ... that the US Patent// and Trademark Office has made a ... stem cells granted in the last few years. ,Patent ... on the works of James A.Thomson of the University of ...
... Chronic constipation affects 15 to 20 percent of the ... defecation, in which muscles used// for bowel movements do ... be relieved now, as the new research shows biofeedback ... was better than standard treatment of laxatives, diet and ...
... may boost the likelihood of heart problems in high ... studies have suggested that ibuprofen interferes with the effects ... cardiovascular health over one year of more than 18,000 ... patients were taking part in the Therapeutic Arthritis Research ...
... have carried out the world's first successful heart surgery to ... operation was performed at Siriraj Hospital on February 20 by ... than 50 days later the separated twins were still in ... the world that doctors have successfully separated Siamese twins joined ...
... antigen (PSA) in a man’s bloodstream at the time ... change over the course of the disease// does not ... in the April 4 Journal of the National Cancer ... cancer have high long-term survival rates, many patients undergo ...
Other Medicine News:Health News:Biofeedback Treats One Type Of Chronic Constipation 2Health News:Biofeedback Treats One Type Of Chronic Constipation 3Health News:Painkiller may Boost Chance of Heart Problems in Patients With Osteoarthritis 2Health News:PSA Not a Good Predictor of Lethal Prostate Cancer 2
Inquire...
... Multifocal IOL was designed to provide a ... glasses in most situations. While distance vision ... to that of a single vision monofocal ... and about 19 in 20 people with ...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
... Zeus Scientific, Inc. Measles test ... qualitative and quantitative detection of ... by the indirect fluorescent antibody ... determine or confirm recent infection ...
Medicine Products: